I-Mab (NASDAQ:IMAB) Stock Position Boosted by Nomura Holdings Inc.
I-Mab (NASDAQ:IMAB) Stock Position Boosted by Nomura Holdings Inc.
Nomura Holdings Inc. boosted its stake in I-Mab (NASDAQ:IMAB – Get Rating) by 0.3% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,613,214 shares of the company's stock after buying an additional 8,000 shares during the period. Nomura Holdings Inc. owned 3.14% of I-Mab worth $10,479,000 at the end of the most recent quarter.
根據最近向證券交易委員會提交的文件，野村控股有限公司在第三季度將其在 I-MAB（NASDAQ：IMAB-獲得評級）的股份提高了 0.3%。該機構投資者於期內額外購入 8,000 股股票後，持有該公司股票 2,613,214 股。野村控股股份有限公司於最近一季末持有 I-MAB 的 3.14%，價值 10,479,000 美元。
A number of other institutional investors and hedge funds have also recently bought and sold shares of IMAB. Northwestern Mutual Wealth Management Co. acquired a new stake in I-Mab in the 2nd quarter valued at about $45,000. Acadian Asset Management LLC acquired a new stake in I-Mab in the 1st quarter valued at about $65,000. ExodusPoint Capital Management LP acquired a new stake in I-Mab in the 3rd quarter valued at about $42,000. OLD Mission Capital LLC acquired a new stake in I-Mab in the 3rd quarter valued at about $45,000. Finally, Virtus ETF Advisers LLC lifted its holdings in I-Mab by 265.0% in the 2nd quarter. Virtus ETF Advisers LLC now owns 11,446 shares of the company's stock valued at $129,000 after acquiring an additional 8,310 shares during the last quarter. Institutional investors own 37.02% of the company's stock.
一些其他機構投資者和對沖基金最近還買賣 IMAB 的股票。西北互惠財富管理有限公司在第二季度收購了 I-MAB 的新股份，價值約為 45,000 美元。阿卡迪亞資產管理有限責任公司在第一季度收購了 I-MAB 的新股份，價值約為 65,000 美元。ExoDusPoint 資本管理有限公司在第三季度收購了 I-MAB 的新股份，價值約為 4.2 萬美元。舊使命資本有限責任公司在第三季度收購了 I-MAB 的新股份，價值約為 45,000 美元。最後，維圖斯 ETF 顧問有限責任公司在第二季度將其對 I-MAB 的持有量提高了 265.0％。維圖斯 ETF 顧問有限責任公司現在擁有該公司的 11,446 股股票，價值為 129,000 美元，在上一季度額外獲得 8,310 股股票後。機構投資者擁有公司股票的 37.02%。
I-Mab Price Performance
最佳價格性能
Shares of NASDAQ IMAB opened at $3.70 on Friday. I-Mab has a twelve month low of $3.19 and a twelve month high of $21.44. The firm has a 50-day moving average of $5.29 and a two-hundred day moving average of $4.63.
納斯達克 IMAB 的股票上週五以 3.70 美元開盤。美國商業銀行有十二個月低點 3.19 美元，十二個月新高為 21.44 美元。該公司的 50 天移動平均線為 5.29 美元，兩百日移動平均線為 4.63 美元。
I-Mab Profile
單點設定檔
(Get Rating)
(取得評分)
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial.
I-Mab 是臨床階段生物製藥公司，致力於發現、開發並將生物製劑商業化，以治療癌症和自身免疫性疾病。它正在開發適用於膜性腎病患者的 CD38 抗體 1b/2a 期；Eftansomatropin Alfa 是一種長效人類生長激素，已完成治療兒科生長激素缺乏症的 3 期臨床試驗；TJ107 是一種重組人類 IL-7，用於癌症治療相關的治療和淋巴細胞免疫治療和癌症免疫減少症；立單抗，已完成 2 期臨床試驗的 CD47 單克隆抗體。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on I-Mab (IMAB)
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
- How to Buy High Yielding Dividend Stocks
- 免費索取有關「創新」的研究報告
- 市場節拍週的回顧 — 3/6 — 3/10
- 2 海上鑽探股票將提取巨額利潤
- 前面有兩位數字的三個主要股票
- 投資者可以信任消費者提升美國戶外品牌嗎？
- 如何購買高收益股息股票
Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.com's FREE daily email newsletter.
接收有關 I-MAB 日報的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 I-Mab 和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。